Position in LYEL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,335,204
+$1,119,702 QoQ
Shares Held
116,411
+194.8% QoQ
Ownership
0.499%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RENAISSANCE TECHNOLOGIES LLC holds $3,467,670,450 across 330 Biotechnology names. LYEL ranks #134 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
13,726,993 | $588,750,729 | |
| 2 | INCY |
Incyte Corp
|
3,651,532 | $343,682,191 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
5,682,783 | $229,072,982 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
421,688 | $188,300,559 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
819,374 | $154,902,654 | |
| 6 | GMAB |
Genmab A/S
|
4,414,550 | $118,442,376 | |
| 7 | INVA |
Innoviva, Inc.
|
4,055,632 | $94,496,225 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
1,036,495 | $64,988,236 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,335,204 | 116,411 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,215,502 | 39,490 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,039,197 | 63,990 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $593,959 | 67,190 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||